The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes (S&P 500, Nasdaq Composite, and Dow Jones), the Nasdaq-100 has grown in popularity over the years because of its concentration of tech stocks (almost 60%), many of which have seen their valuations skyrocket in recent years.
Through Nov. 22, the Nasdaq-100 is up over 23%, which is impressive for a broad index. However, it hasn't been peachy keen for all companies in the index. Here are the worst-performing stocks in the Nasdaq-100 so far this year:
| Company | Stock Price Decrease |
|---|---|
| Moderna (MRNA -0.33%) | (61.54%) |
| Intel (INTC -0.37%) | (51.36%) |
| DexCom (DXCM -0.62%) | (40.00%) |
| Biogen (BIIB 0.85%) | (38.94%) |
| Lululemon Athletica (LULU -0.01%) | (38.36%) |
Data source: Finviz. Stock price decreases as of Nov. 22.
Be aware of the near term, but play the long game
Nobody likes to see their stocks on a "worst-performing" list, but it doesn't always mean all hope is lost for a company or your investment. People -- and, therefore, the stock market -- are notoriously irrational. A stock price decline doesn't always mean a company is on the decline; plenty of factors could come into play.
If you take a deeper dive into the "why" behind a price slump and a company seems to be heading in the wrong direction, then, by all means, jump ship if you feel the need.
However, if you still believe in the company's long-term potential, don't jump ship just because of a stock price slump. If anything, you could use this as a time to buy some shares at a "discount" or potentially lower your cost basis.
One year is a relatively short period when you're investing for the long term. It helps to be aware of a stock's short-term performance, but you don't want to make any short-term decisions that go against your long-term best interest. Keep the end goal in mind.
